LinkOPH

One-year findings of the LUMINOUS study, the first global, large-scale observational study on ranibizumab in routine clinical practice, showed good disease control, with maintained or increased vision and a complication rate comparable to that of clinical trial settings. The study is gradually recruiting a total of 30,000 patients with age-related macular degeneration, diabetic macular edema and retinal vein occlusion over a period of 3 years, with a possible extension to 4 years and an additional 10,000 patients. The United Kingdom, Canada, Australia, China and Russia are involved, and other countries (Read more...)

VIENNA — High-definition spectral-domain optical coherence tomography analysis helped clarify mechanisms and risk factors of retinal pigment epithelium tears occurring in fibrovascular pigment epithelium detachment, according to one specialist. “Fibrovascular PED develops tears in 10% to 15% of the eyes in a variety of retinal disorders. They tend to grow over time, with significant consequences on vision. As they reach the large diameter of grade 3 and 4, they are difficult to treat,” David Sarraf, MD, said at the Advanced Retinal Therapy meeting.

Read more →

VIENNA — VEGF inhibitors are now first-line therapy for center-involved diabetic macular edema with reduced vision, and treatment protocols are rapidly evolving. However, data regarding many aspects of initiation, cessation and restarting of therapy remain unknown, a speaker said at the Advanced Retinal Therapy meeting here. The Diabetic Retinopathy Clinical Research Network (DRCR.net) protocol trial demonstrated that Lucentis (ranibizumab, Novartis/Genentech) with deferred or prompt focal/grid laser resulted in superior visual acuity outcomes compared with laser alone, Lloyd A. Aiello, MD, said. Over 3 years, more than half of the eyes (Read more...)